Following the first report of successful intracoronary stenting in humans, there was early enthusiasm for the potential of this technology to prevent occlusion or restenosis following angioplasty. Such enthusiasm however was quickly tempered by concerns regarding early thrombotic stent occlusion and its associated high risk of myocardial infarction or death, following the report of a 24% incidence of stent thrombosis in the first 105 patients receiving the Wallstent.' An almost simultaneous report of the first 226 patients receiving a PalmazSchatz stent showed an 18% rate of stent thrombosis in patients treated with aspirin and dipyridamole, with a dramatic improvement to only 0-6% following the addition of warfarin. As management of thrombotic stent occlusion proved to be consistently associated with a poor outcome, a concerted effort was directed towards its prevention through more aggressive antithrombotic regimens. Despite experimentation with a wide variety of regimens, which included combinations of heparin, urokinase, dextran, warfarin, aspirin, dipyridamole, and sulphinpyrazone, stent thrombosis continued to occur in roughly 4% of patients. Also, these intense antithrombotic protocols contributed to a 10-30% incidence of vascular complications as well as a substantial prolongation of hospital stays. It was not until after successful stent placement was reported using only antiplatelet therapy in conjunction with intravascular ultrasound guidance to assure optimal stent deployment that the trend towards increasing anticoagulation began to reverse. Clinical application of antiplatelet therapy Despite the excessive incidence of stent thrombosis seen during the early experience in patients treated with the antiplatelet combination of aspirin and dipyridamole, a new antiplatelet regimen combining ticlopidine and aspirin began to be re-evaluated when optimal stent expansion using high pressure balloon dilatations was employed. Because data from the initial, non-randomised evalua- tions of this regimen consistently demonstrated subacute stent thrombosis rates of less than 2% as well as a major reduction in bleeding complications, combined ticlopidine and aspirin quickly became the accepted antiplatelet regimen.
To establish definitely the superiority of antiplatelet rather than anticoagulant therapy following intracoronary stenting, three prospective, randomised trials were designed, which together enrolled over 2600 patients. Although minor variations in design existed between the studies, all compared outcomes in successfully stented patients for a variety of clinical indications, and all employed at least a ticlopidine/aspirin arm and an intravenous heparin/oral vitamin K antagonist/aspirin arm. Each study demonstrated a significant reduction in the primary cardiac end point (death, myocardial infarction, or revascularisation) at 30 days in the combined antiplatelet arm compared with the anticoagulant arm (table 1). In the only published results to date, the Intracoronary Stenting and Antithrombotic Regimen (ISAR) trial reported no haemorrhagic complications in the antiplatelet treated group, compared with a 6-5% incidence in the anticoagulant arm.8 Although the results of these trials have confirmed the beneficial role of antiplatelet compared with anticoagulant treatment in minimising both stent thrombosis and haemorrhagic complications, several issues still remain regarding the optimal antiplatelet strategy.
Despite the encouraging results seen with the combination of ticlopidine and aspirin, concerns over the risk of ticlopidine associated leucopenia, which occurs in up to 2-5% of patients and is occasionally irreversible, prompted evaluation of whether ticlopidine provided incremental benefit to aspirin alone. Early trials comparing aspirin alone versus aspirin and ticlopidine suggested no difference between the treatment strategies, but these studies involved small numbers of patients and were inadequately powered. The prospective, randomised Stent Anticoagulation Regimen Study (STARS) enrolled 1652 patients and investigated three antithrombotic strategies (table 1) ; aspirin plus ticlopidine was superior to antithrombotic therapy or aspirin alone (presented at the American Heart Association scientific sessions, November 1996). Interestingly, the aspirin treatment group had the highest incidence of the primary cardiac end point. This outcome is consistent with the results of a porcine carotid stent injury study which suggested a strong synergy between ticlopidine and aspirin in limiting platelet deposition and thrombosis (personal communication, Schwartz RS, 1996) .
Although the addition of ticlopidine to aspirin is clearly beneficial, the duration of treatment as well as the optimal time to start therapy has yet to be clearly established. The antiplatelet effects of ticlopidine are dose and time dependent, with near maximal platelet inhibition not achieved until after four days of therapy. Although the results of randomised trials prove that starting ticlopidine at the time of stent placement is adequate for preventing stent thrombosis, preliminary data from our institution suggests that starting ticlopidine several days before the procedure significantly decreases the incidence of asymptomatic but clinically significant post-procedural non-Q wave myocardial infarctions. Also, as stent thrombosis typically occurs within the first week following placement, treatment may not be required for up to four to six weeks as was used in the randomised trials. Limiting the duration of therapy would likely also reduce side effects, as leucopenia secondary to ticlopidine is typically not seen until after two weeks of treatment. Observational data has thus far supported the continued clinical efficacy and improved safety of two weeks of ticlopidine therapy. Further prospective data will be required before the optimal timing of therapy initiation as well as duration of therapy is clearly defined. lesions with a substantial thrombus burden, culprit lesions in acute coronary syndromes, and saphenous vein grafts (especially degenerated vein grafts). The use of multiple overlapping stents or a suboptimal result after stenting are other situations where abciximab is often used.
Future directions

Conclusions
Our knowledge of the physiological response elicited by intracoronary stent placement at both the clinical and molecular level has increased dramatically since the first use of this technology in humans almost 10 years ago. This knowledge has helped us to tailor our technique as well as adjunctive therapies to optimise stenting outcomes. As we continue to explore other avenues for improving coronary stenting, and apply what is learned to clinical practice, stent implantation will approach the ideal as a means to prevent occlusion or restenosis following angioplasty.
